Nunzia Pharmaceutical Company
NUNZ
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 119,918.19% | 181,479.36% | 201,500.63% | 198,527.99% | 236.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 119,918.19% | 181,479.36% | 201,500.63% | 198,527.99% | 236.67% |
| Operating Income | -119,918.19% | -181,479.36% | -201,500.63% | -198,527.99% | -236.67% |
| Income Before Tax | 4.03% | 4.20% | 4.21% | 22.72% | -420,974.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.03% | 4.20% | 4.21% | 22.72% | -420,974.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.03% | 4.20% | 4.21% | 22.72% | -420,974.17% |
| EBIT | -119,918.19% | -181,479.36% | -201,500.63% | -198,527.99% | -236.67% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 24.60% | 24.70% | 24.70% | 36.82% | -- |
| Normalized Basic EPS | 24.56% | 24.62% | 24.62% | 36.81% | -- |
| EPS Diluted | 24.60% | 24.70% | 24.70% | 36.82% | -- |
| Normalized Diluted EPS | 24.56% | 24.62% | 24.62% | 36.81% | -- |
| Average Basic Shares Outstanding | 43.38% | 31.99% | 19.77% | 6.67% | -8.89% |
| Average Diluted Shares Outstanding | 43.38% | 31.99% | 19.77% | 6.67% | -8.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |